List view / Grid view
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The primary endpoint of the trial being the percentage of patients who achieved a sustained virologic response 12 weeks after treatment (SVR12)...
9 August 2016 | By MSD
Following successful phase 3 clinical trials, in which MSD’s new Hepatitis C drug, Zepatier, performed well, achieving high virologic cure rates across the study, the European Commission has licensed the drug for sale in the European market, specifically for the treatment of chronic hepatitis C virus (HCV) in adults with…
28 July 2016 | By Niamh Louise Marriott, Digital Content Producer
To find out more about Hepititis C, European Pharmaceutical Review spoke with Raquel Peck, CEO of the World Hepatitis Alliance and discovered exactly what it is being done to combat this widespread global health issue...
